New Horizon Health Limited, a vendor in China that focuses on non-invasive colon cancer screening technology, inked an exclusive deal with Prenetics Limited, a genetics and digital health company in Asia and Europe. New Horizon will undertake a technology transfer to Prenetics for its ColoClear, non-invasive multi-target stool DNA test for colorectal cancer, developed for individuals of Asian ethnicity and, they purport, to be “validated through clinical studies to perform at 92% sensitivity in the detection of colon cancer.”
In addition to the technology transfer, Prenetics will set up a ISO-15189 accredited, dedicated colon cancer detection service facility in Hong Kong by early 2020 and another one in Southeast Asia later in the year.
Non-Invasive Colon Cancer Detection: Who is New Horizon Health Limited?
Based in Hangzhou, China (near Shanghai), New Horizon Health Limited was founded in 2013 with a mission to make non-invasive, DNA test-based colon cancer detection technology available. They believe their ColoClear “is a true technology Game Changer in terms of performance” and that can be accessible to million of people throughout the Asian continent.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).